Entrada Therapeutics, Inc. · NASDAQ:TRDA
Entrada Therapeutics — CureDuchenne FUTURES 2023
11 slides from Entrada Therapeutics's conference presentation, 2023
Slide 1: Endosomal Escape Vehicle (EEV) Platform for Delivery of Oligonucleotides in Duchenne Muscular Dystrophy
Endosomal Escape Vehicle (EEVTM) Platform for Delivery of Oligonucleotides in Duchenne Muscular Dystrophy Nerissa Kreher, MD, MBA Chief Medical Officer Entrada Therapeutics, Inc. WANT TO LEARN MORE? Scan the QR code for access to our recent publications and conference presentations. 1 CureDuchenne F
Slide 2: Disclaimer
DISCLAIMER This presentation includes express and implied “forward-looking statements. Forward looking statements include all statements that are not historical facts, and in some cases, can be identified by terms such as “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,
Slide 3: Who We Are
WHO WE ARE Our Commitment Our Culture Our Team • Developing treatments for • We are building a company • ~130 employees with an people living with serious culture where everyone can experienced leadership team diseases for which no or belong, contribute and grow insufficient options currently • Reco
Slide 4: Our Commitment to the Duchenne Community
OUR COMMITMENT TO THE DUCHENNE COMMUNITY Our partnerships with community leaders and patient advocacy organizations are at the heart of our work to bring innovative therapies to people living with devastating diseases ENTR-601WeeweWe-44ENTR-601-44 We appreciate the Duchenne community’s PURSUING TREA
Slide 5: Intracellular Therapeutics May Present a Solution
INTRACELLULAR THERAPEUTICS MAY PRESENT A SOLUTION Approximately 75% of all disease-causing targets are within the cell and difficult to reach, representing a significant challenge when developing effective therapies First Challenge: Cell Entry Early Endosome Second Challenge: ~75% of Disease Targets
Slide 6: Our Endosomal Escape Vehicle (EEV) Platform
OUR ENDOSOMAL ESCAPE VEHICLE (EEV TM) PLATFORM We are developing EEV-oligonucleotide conjugates for the treatment of Duchenne • EEV-oligonucleotide conjugates are cyclic Prolonged duration of effect Improved entry into the cell 3 peptides attached to oligonucleotides (intracellular depot) 1 (~90% up
Slide 7: ENTR-601-44 Is Our Exon Skipping Clinical Candidate
ENTR-601-44 IS OUR EXON 44 SKIPPING CLINICAL CANDIDATE A single IV dose of ENTR-601-44 resulted in robust exon skipping in both skeletal and cardiac muscles in non-human primates (NHP), as well as prolonged duration of effect for at least 12 weeks Exon Skipping in Muscles at Day 7 Duration of Effect
Slide 8: Preclinical Data Support Advancement of ENTR-601-44 to the Clinic
PRECLINICAL DATA SUPPORT ADVANCEMENT OF ENTR-601-44 TO THE CLINIC Results show: Effective exon Robust dystrophin Prolonged duration of skipping seen in production observed effect, which may skeletal, in skeletal muscle translate to diaphragm and cells from patients administration of drug heart muscl
Slide 9: ENTR-601-45 Effective in Skeletal and Cardiac Muscle Cells
ENTR-601-45 EFFECTIVE IN SKELETAL AND CARDIAC MUSCLE CELLS ENTR-601-45 showed robust exon skipping and dystrophin production in skeletal and cardiac muscle cells from patients living with Duchenne who are amenable to exon 45 skipping ENTR-601-45 in Skeletal Muscle Cells ENTR-601-45 in Cardiac Muscle
Slide 10: In Summary
IN SUMMARY Entrada lead programs are advancing new therapeutic options for people living with exon 44 and exon 45 skip amenable Duchenne • ENTR-601-44 produced robust exon skipping and dystrophin production in cell and animal models of Duchenne • We observed robust exon skipping over 12+ weeks from
Slide 11: Thank You From Our Whole Team
THANK YOU FROM OUR WHOLE TEAM Please visit us during the exhibitor showcase later this afternoon! WANT TO LEARN MORE? Scan the QR code for access to our recent publications and conference presentations. For questions, contact: Regan Sherman, Head of Patient Advocacy, rsherman@entradatx.com 11 CureDu